Antibody Discovery

The therapeutic antibody landscape has expanded rapidly, with monoclonal antibodies (mAbs) established as a dominant class of biologics across oncology, autoimmune, and infectious diseases. At the same time, the number of investigational antibody candidates continues to increase, placing pressure on development pipelines to deliver candidates efficiently.

Discover the efficiency of AbDrop™ and HUGO-Ab™ for rapid, fully human antibody discovery using microfluidics and TurboKnockout® technology with results in as little as 3 months.

Learn how TCR-like antibodies target intracellular tumor antigens through pMHC recognition. Explore their role, development, and potential in immunotherapy.

Examine how antibody discovery supports CAR-T cell engineering by improving target specificity, reducing toxicity, and advancing next-generation cancer immunotherapies.

Learn how transgenic animals are transforming antibody discovery by generating fully human antibodies for biomedical research, diagnostics, and drug development.

Explore cutting-edge antibody discovery technologies and trends—hybridoma, phage display, single B cell tech, and AI innovations in driving therapeutic breakthroughs.